Related by context. All words. (Click for frequent words.) 63 Allovectin 7 63 deforolimus 62 targeted radiotherapeutic 61 Phase Ib study 61 Fodosine 61 CVac 60 BAY #-# 60 PSMA ADC 60 Proxinium TM 60 SUCCEED trial 60 Phase IIb clinical trials 60 mertansine 60 RSR# 60 Corlux 60 phase IIb clinical 60 Phase #b/#a clinical 59 IL# PE#QQR 59 Zybrestat 59 DPX Survivac 59 Civacir 59 Aflibercept 59 Canvaxin 59 lorvotuzumab mertansine 59 PF # [002] 59 CA9 SCAN 59 Tykerb lapatinib 59 Ventrus 58 Troxatyl 58 BLP# Liposome Vaccine 58 Phase Ib II 58 Provecta 58 Aplidin 58 Harry Palmin President 58 Pertuzumab 58 midstage clinical 58 Clolar ® 58 Alocrest 58 phase IIb trial 58 Nanobody 58 docetaxel Taxotere R 58 nalbuphine ER 58 Quinamed 58 Nexavar sorafenib 58 romidepsin novel 58 lumiliximab 58 oral ridaforolimus 58 Cloretazine ® 58 Dacogen decitabine 58 NP2 Enkephalin 58 Mipomersen 58 pertuzumab 58 Panzem 58 BioNumerik 58 huC# DM4 58 BrachySil TM 58 IMA# 58 hepatitis B vaccine Heplisav 57 trastuzumab DM1 57 Ceflatonin 57 depsipeptide 57 StemEx R 57 Panzem R NCD 57 Aurexis 57 thetreatment 57 Desmoteplase 57 Factor VIIa 57 CBLC# 57 BRIM2 57 cediranib 57 Xerecept 57 NV1FGF 57 CytoFabTM 57 OMS#HP 57 Gleevec imatinib mesylate 57 novel therapeutic antibodies 57 BRAF inhibitor 57 phase IIa clinical 57 Oncogenex 57 Omnitarg 57 Solazed 57 photoprotective drug 57 ularitide 57 antibody MAb 57 Vectibix panitumumab 57 alvespimycin 56 Abiraterone acetate 56 Onconase 56 Onrigin 56 Personalized Immunotherapy 56 Bezielle 56 seliciclib CYC# 56 WILEX 56 Omacetaxine 56 YONDELIS 56 Annamycin 56 vinorelbine tartrate 56 immunotherapeutic vaccine 56 OvaRex R 56 reslizumab 56 dexanabinol 56 eniluracil 56 elotuzumab 56 macitentan 56 Phase IIIb clinical 56 therapeutic monoclonal antibody 56 GRN# 56 Medidur FA 56 Provenge prostate cancer 56 SinuNase ™ 56 EndoTAG TM -1 56 rALLy clinical trial 56 trastuzumab DM1 T DM1 56 Urocidin 56 OvaRex ® MAb 56 midstage studies 56 immatics 56 INCB# [001] 56 omacetaxine mepesuccinate 56 YONDELIS R 56 EndoTAGTM 1 56 OncoVex 56 EndoTAG TM 56 OMP #R# 56 multiple myeloma MM 56 volociximab 56 Daclizumab 56 ThermoDox R 56 bortezomib Velcade 56 Hemospan 56 midstage clinical trials 56 TASKi3 56 TBC# 56 Xcellerated T Cells 56 Angiocept 56 neratinib 56 RIGScan CR 55 MyVax 55 PDE4 inhibitor 55 pain palliation 55 Litx 55 VALSTAR 55 ALN PCS 55 OMP #M# 55 HuMax CD4 55 pediatric acute lymphoblastic 55 vemurafenib 55 incyclinide 55 KNS # 55 StemEx 55 multicenter Phase II 55 pharmacokinetic PK study 55 sorafenib Nexavar 55 GVAX 55 vaccine Stimuvax 55 GALNS 55 adjuvant colon cancer 55 Ocrelizumab 55 MKC# MKC# PP 55 Raf kinase inhibitor 55 IIa trial 55 cancer immunotherapies 55 Nuvion 55 Tesetaxel 55 Tocosol Paclitaxel 55 midstage clinical trial 55 Adventrx 55 Pimavanserin 55 alemtuzumab Campath 55 Diamyd R 55 phase IIb study 55 OncoGel 55 MyVax personalized immunotherapy 55 Qutenza TM 55 GRNVAC1 55 VitiGam 55 KRN# 55 BEMA TM Fentanyl 55 brentuximab 55 investigational humanized monoclonal antibody 55 Arzerra ofatumumab 55 Pirfenidone 55 randomized controlled Phase 55 PhG alpha 1 55 GLP1 agonist 55 Ketotransdel 55 optimal dosing regimens 55 Lung Rx 55 EOquin TM 55 REOLYSIN ® 55 Archexin 55 metastatic malignant 55 inhaled AAT 55 Xcytrin R 54 Neuvenge 54 Phase IIB 54 oral prodrug 54 Degarelix 54 budesonide foam 54 StaphVax 54 Phase IIa trial 54 HuMax EGFr 54 NeuVax 54 BCR ABL inhibitor 54 Sudhir Agrawal D.Phil 54 concurrent chemoradiation 54 huN# DM1 54 Vitaxin 54 Zarnestra 54 PANVAC VF 54 experimental lupus 54 initiated Phase Ib 54 assessing T DM1 54 Curaxin 54 CoAxia 54 Onalta ™ 54 Nasdaq OPTR 54 ocrelizumab 54 SAR# [004] 54 Memryte 54 ABX EGF 54 Iloperidone 54 5 fluorouracil leucovorin 54 lomitapide 54 Vernakalant 54 Aryx 54 Orathecin 54 SNT MC# 54 LymphoStat B TM 54 experimental hepatitis C 54 tubulin inhibitor 54 TransMID 54 PNT# 54 AFRS TM 54 Saforis 54 acyclovir Lauriad R 54 phase IIb 54 EP #R 54 octreotide implant 54 FORTIS M trial 54 NovoTTF 54 Tarceva TM 54 BrachySil 54 PFO migraine 54 Exherin TM 54 angiogenesis inhibitor 54 forodesine 54 Dacogen injection 54 ATL# [001] 54 Xelox 54 registrational trial 54 HGS ETR1 54 antibiotic telavancin 54 GVAX ® 54 Levadex 54 RhuDex ® 54 beta 1a 54 PI3K/Akt pathway inhibitor 54 tiapamil 54 Trofex 54 Eligard prostate cancer 54 vidofludimus 54 Avastin adjuvant 54 #I TM# 53 IIb clinical trial 53 registrational 53 IMC #B 53 Fibrillex 53 ToGA 53 phase IIa 53 Muraglitazar 53 OncoVEX 53 including eniluracil ADH 53 ITAX 53 Phase 2b clinical 53 ENDEAVOR IV 53 JAK inhibitor 53 PNP inhibitor 53 Cardio Vascu Grow 53 Cinquil 53 Excellagen 53 Prosaptide 53 Onalta 53 molecular imaging radiopharmaceuticals 53 biliary tract cancer 53 tranilast 53 ospemifene 53 novel oral anticoagulant 53 afamelanotide 53 liposomal formulation 53 entinostat 53 Neo Bladder Augment 53 mTOR inhibitor 53 Allovectin 7 R 53 Veronate 53 cannabinor 53 antisense drug 53 Crizotinib 53 OraTest 53 systemic anaplastic large 53 ProSavin 53 Phase Ib 53 Tocosol 53 novel peptide 53 Phase III Pivotal 53 Alvesco R 53 baminercept 53 evaluating tivozanib 53 Virulizin 53 initiate Phase 1b 53 Aryplase 53 MAGE A3 ASCI 53 CRD5 53 PDE# inhibitors 53 Immunotherapeutic 53 PrevOnco ™ 53 tremelimumab 53 immunotherapeutic agent 53 initiate Phase Ib 53 ABSORB trial 53 targeted antifolate 53 targeting CD# 53 Curaxin CBLC# 53 Diamyd ® 53 sitaxsentan 53 PS# DARA 53 Pivotal Phase III 53 OHR/AVR# 53 CytoFab ™ 53 tolevamer 53 Cand5 53 randomized Phase IIb 53 CRMD# 53 Icatibant 53 anticancer compound 53 selective S#P# receptor agonist 53 Oncotype DX colon cancer 53 oral picoplatin 53 overactive bladder AA# 53 BRIM3 53 JAK inhibitors 53 PEGylated 53 Zemplar Capsules 53 CAPHOSOL R 53 Phase IIa proof 53 Temsirolimus 53 Abiraterone 53 Phase #b/#a 53 Loramyc R 53 Pivotal Trial 53 multi kinase inhibitor 53 preclinically 53 chemical entities NCEs 52 NP2 52 Juvaris BioTherapeutics 52 OncoVEX GM CSF 52 Phase Ib clinical 52 TASQ 52 TACI Ig 52 neurogenic orthostatic hypotension 52 dose escalation clinical 52 Surfaxin LS 52 Factor Xa inhibitor 52 MIST II 52 Panacos Pharmaceuticals 52 ACCLAIM II 52 PRECISE trial 52 ocular formulation 52 Curis CRIS 52 Anavex #-# 52 HGS# 52 Uplyso 52 Elagolix 52 midstage trials 52 Unit Dose Budesonide 52 rilonacept 52 Proellex TM 52 Juvista 52 PrevOnco 52 Pivotal Study 52 bardoxolone 52 Vaxfectin TM 52 NPC 1C 52 non nucleoside inhibitor 52 ongoing Phase 1b 52 GSK# [002] 52 Zenvia ™ 52 Cetrorelix 52 Removab 52 Tolamba 52 Affinitak 52 Thiarabine 52 Vibativ 52 DermaVir Patch 52 phase Ib clinical 52 Dendreon Provenge 52 torezolid 52 Motesanib 52 Phase III registrational 52 solanezumab 52 rhThrombin 52 phase 2a 52 Fx #A 52 IMiD 52 ketoprofen patch 52 oncolytic virus therapies 52 ChronVac C R 52 oral treprostinil 52 HepeX B 52 IND submission 52 Catabasis 52 multicenter Phase 52 HuMax CD# 52 INS# [001] 52 renal denervation 52 acyclovir Lauriad ® 52 DepoMed 52 phase Ib 52 TRIST study 52 Spiegelmer ® 52 dose escalation Phase 52 Phase 2a trial 52 Alnylam #x# 52 oral salmon calcitonin 52 HDL Selective Delipidation 52 PLX# 52 Cx# [002] 52 Phase 1b trial 52 Alzhemed TM 52 PTK# 52 compound INCB# 52 Virulizin ® 52 aerosolized KL4 surfactant 52 JAK2 inhibitor 52 proteasome inhibitor 52 Anti VEGF 52 AzaSite Plus 52 Evoltra ® 52 gepirone ER 52 Capesaris 52 FIRMAGON R 52 methylnaltrexone 52 confirmatory Phase III 52 TRANSDUR Bupivacaine 52 Phase IIa clinical 52 Squalamine 52 molecular imaging radiopharmaceutical 52 ATL# [002] 52 JAK3 inhibitor 52 Luveniq 51 LHRH antagonist 51 Phase 1a clinical 51 Guanilib 51 EGS# 51 figitumumab 51 Panzem R 51 MelaFind R 51 HQK 51 JZP 51 brivaracetam 51 mTOR inhibition 51 cariprazine 51 trial evaluating PRX# 51 ABthrax TM raxibacumab 51 trodusquemine 51 farletuzumab 51 PRESEPT 51 Sym# 51 DCVax 51 bicifadine 51 sterile lidocaine patch 51 NEUGENE R 51 virus HCV protease inhibitor 51 FTY# fingolimod 51 UPLYSO 51 tasisulam 51 generation purine nucleoside 51 SCIB1 51 Phase III psoriasis 51 Tragara 51 intranasal formulation 51 Tarvacin TM 51 prostone 51 Urocortin 2 51 QLT# 51 Phase IIb trials 51 Orazol 51 Amplimexon 51 molecular radiotherapeutics 51 AeroLEF TM 51 MT# MEDI 51 PD LID 51 cilengitide 51 punctal plug delivery 51 Valtropin 51 clazosentan 51 ThGRF 51 humanised monoclonal antibody 51 Phase IIb III 51 Aveo Pharmaceuticals 51 LUMINATE 51 phase IIIb 51 elacytarabine 51 anticoagulant reversing agent 51 LBH# 51 PORxin TM 51 SinuNase TM 51 RAV# 51 IIa trials 51 ulimorelin 51 omega interferon 51 DepoBupivacaine 51 initiate Phase IIb 51 ADVEXIN clinical 51 Zensana TM 51 selective androgen receptor modulator 51 SMT C# 51 rALLy trial 51 Phase Ib IIa 51 Phase 1b clinical trials 51 PHX# 51 molecular imaging pharmaceuticals 51 NASDAQ CXSP announced 51 oral methylnaltrexone 51 Alferon N 51 Trastuzumab DM1 51 tezampanel 51 PSN# [001] 51 novel immunotherapeutic 51 Traficet EN 51 ALN VSP Phase 51 Sphingomab TM 51 canagliflozin 51 Ixabepilone 51 Relovair 51 Phase III 51 receptor tyrosine kinase inhibitor 51 oncolytic vaccine 51 orally inhaled migraine 51 delivery polymer matrix 51 atacicept 51 allogeneic cell 51 Epitan 51 Spheramine 51 Alfimeprase 51 Lpathomab 51 LEVADEX TM 51 BLA submission 51 Phase 2b study 51 Gleevec resistant 51 CMV vaccine 51 Micromet BiTE 51 Vascugel 50 interferon beta 1b 50 hematological indications 50 dexpramipexole 50 EECP ® therapy 50 immuno therapeutic 50 drug tesmilifene 50 buccal spray 50 Silodosin 50 Liposomal Grb 2 50 SPIRIT FIRST 50 adrenergic regulation 50 lucinactant 50 evaluating Actimmune 50 pseudobulbar affect PBA 50 Phase 1a 50 anti CD3 antibody 50 anticancer therapeutics 50 Altastaph 50 Homspera TM 50 RELOVAIR ™ 50 Optimata 50 erlotinib Tarceva 50 BLA filing 50 torezolid phosphate 50 GLPG# 50 evaluating satraplatin 50 blood clot preventer 50 DXL# 50 LEVADEX ™ 50 cytokine refractory 50 Deforolimus 50 randomized Phase 2b 50 radezolid 50 alkylating agent 50 MEND CABG II 50 fostamatinib disodium 50 Phase 2b monotherapy 50 Protectan 50 Alequel ™ 50 Dapagliflozin 50 Lupuzor 50 Hedgehog antagonist 50 pivotal Phase III 50 bavituximab monotherapy trial 50 renin inhibitor 50 bioFILM PA TM 50 Neugene 50 Rilutek 50 TELINTRA R 50 MT#/MEDI-# 50 Valdoxan 50 Apoptone 50 MabThera rituximab 50 Phase 2b trial 50 NADiA 50 Initiate Phase 50 Iressa gefitinib 50 Phase 2b clinical trials 50 indibulin 50 EDEMA3 50 TransVax 50 Phase 2b Clinical Trial 50 Humira adalimumab 50 Proteo 50 AMN# [001] 50 Excellarate TM 50 RhuDex 50 Adentri 50 Biopump 50 GeneICE 50 methylnaltrexone bromide 50 APEX PD 50 HCD# [002] 50 NSABP C 50 AFREZZA TM 50 Phase 1b 50 PRECISE Trial 50 catheter occlusion 50 DAC HYP 50 Kamada AAT 50 Argatroban 50 antifibrotic 50 CINQUIL 50 Laquinimod 50 samalizumab 50 Fc fusion protein 50 NXL# 50 Relivar 50 PRIMO CABG 50 peginesatide 50 investigational HCV polymerase 50 Tyzeka Sebivo 50 Olaparib 50 DEEP AF 50 dose cohort 50 EchoCRT 50 Bayer HealthCare Onyx Pharmaceuticals 50 PREOS R 50 Enobia 50 Aplidin R 50 TRX1 50 Sorafenib Nexavar 50 dextromethorphan quinidine 50 hypoxia activated prodrug 50 pradefovir 50 refractory acute myeloid 50 hyaluronidase enzyme 50 fosbretabulin 50 Arranon 50 ganaxolone 50 ATPace TM 50 neuronal nicotinic receptor NNR 50 UVIDEM 50 oral anticancer 50 Hedgehog agonist 50 custirsen 49 BioMatrix 49 placebo controlled Phase 49 RE COVER 49 Aurograb 49 Naproxcinod 49 tezampanel NGX# 49 phosphatidylserine PS targeting 49 triphendiol 49 HuMax TAC 49 ALN TTR# 49 phase IIb III 49 trastuzumab emtansine T DM1 49 DCCR 49 MYDICAR 49 Phase III ADT 49 Tyrima 49 Phase III randomized controlled 49 Cogane 49 inhaled formulation 49 human IgG1 monoclonal 49 GVAX R 49 ONCONASE R 49 Fenretinide 49 AZILECT ® 49 AAG geldanamycin analog 49 Phase Ib clinical trials 49 ADVANCE PD 49 Zemiva 49 Kahalalide F 49 Correlogic 49 preclinical efficacy 49 Phase IIb trial 49 pharmacokinetic PK 49 NVA# 49 sipuleucel T Provenge 49 glucokinase activator 49 AKT inhibitor 49 Prodarsan R 49 Dasatinib 49 eflornithine 49 XmAb 49 PI3K inhibitor 49 follicular Non Hodgkin 49 CCR5 mAb 49 HepDirect prodrug 49 ketolide antibiotic 49 multicenter phase 49 Targacept TRGT 49 Phase III TRIST 49 Zactima 49 exon skipping 49 Phase 2a clinical 49 TLK# 49 Safinamide 49 Dermylex TM 49 rhFVIIa 49 HepaMate 49 paromomycin 49 Pivotal Phase 49 cartilage regeneration 49 CYT# QbG# 49 BBI# 49 intravitreal insert 49 radiolabeled TM# 49 almorexant 49 CML CP 49 generation PNP inhibitor 49 HCV antiviral 49 Novartis NVS Snapshot Report 49 AE# vaccine 49 Xyotax 49 HDL Mimetic Peptide 49 Oglemilast 49 Anturol TM 49 Ataluren 49 RPL# 49 Ostabolin C TM 49 Omapro 49 vaccine Oncophage 49 vivo validation 49 Genz # 49 Lovaxin C 49 HCV protease inhibitor 49 USL# 49 Rezular 49 CRLX# 49 Plicera 49 TransMID TM 49 pafuramidine maleate 49 BNC# 49 2DG 49 ToxCast TM 49 Galenea 49 Cologuard 49 VIR# 49 Ceplene/IL-2 49 Zenvia Phase III 49 SEPET TM 49 Synavive 49 Dextofisopam 49 RezularTM 48 oral ghrelin agonist 48 GAMMAGARD 48 multicenter randomized placebo controlled 48 liprotamase 48 balsalazide tablet 48 blood clot dissolver 48 NeuroFlo 48 sumatriptan DosePro 48 ACV1 48 LB# [003] 48 OncoGenex Technologies 48 M Vax 48 Phase IIa trials 48 Phase IIb clinical 48 Ostarine 48 Novolimus 48 ACAPODENE 48 Phase III pivotal 48 PEARL SC 48 Phase #/#a 48 Lucanix R 48 blood thinner Brilinta 48 Anacetrapib 48 CHAMPION PCI 48 delafloxacin 48 ESBA# 48 Phase III clinical 48 Phase III Clinical Trial 48 Vertex hepatitis C 48 Phase lll 48 MediWound 48 RNAi therapeutic targeting PCSK9 48 FRDA 48 OMAPRO ™ 48 cetrorelix pamoate 48 blood thinner Xarelto 48 Akt inhibitor 48 IIa clinical trial 48 investigational transdermal 48 systemic RNAi therapeutic 48 Lu AA# 48 Alzhemed 48 rPA anthrax vaccine 48 dose escalation phase 48 Prodarsan ® 48 myoblast 48 Endoscopic Ablation System 48 lesinurad 48 novel VDA molecule 48 Intravail R 48 ACCEDE 48 GeoVax vaccine 48 BiTE R 48 EMPOWER Study 48 virotherapy 48 preclinical pharmacokinetic 48 CIP TRAMADOL ER 48 HuCAL antibodies 48 FDG PET imaging 48 Ilaris ® 48 NeuroSTAT ® 48 ZFP Therapeutics 48 nucleoside analog 48 rotary VAD 48 nucleotide analogue 48 investigational antibiotic 48 Phase III confirmatory 48 bioresorbable stent 48 fostamatinib 48 Hedgehog pathway inhibitor 48 GLP toxicology studies 48 tramiprosate Alzhemed TM 48 Acetavance TM intravenous acetaminophen 48 drug belatacept 48 Novo TTF 48 NuroPro R 48 resminostat 48 Aurora kinase inhibitors 48 Menerba 48 antiangiogenesis 48 cathepsin K inhibitor 48 Oral NKTR 48 dose escalation trial 48 BR.# 48 NSCLC tumors 48 adipiplon 48 PEGylated interferon 48 romazarit 48 confirmatory Phase 48 BiTE 48 Nanocort 48 NASDAQ NVAX 48 Ultrafast Insulin 48 ENRICH trial 48 initiate Phase 2b 48 intra arterial chemotherapy 48 Elvitegravir 48 imexon 48 Mammosite 48 adjuvant cisplatin 48 Dalbavancin 48 ASPIRE HIGHER 48 QUASAR validation study 48 hoFH 48 isavuconazole 48 SAR# [002] 48 initiate Phase IIa 48 CLIRS 48 multicenter clinical 48 Liprostin 48 paclitaxel poliglumex 48 RSD# 48 CLIRS trial 48 Phase IIIb study 48 ASONEP 48 BHT DNA 47 lorcaserin Phase 47 Intraject 47 Bazedoxifene 47 Phase 2a Clinical Trial 47 blood thinner prasugrel 47 Ampakine compounds 47 aurora kinase 47 TOLAMBA 47 CCX# B 47 Alequel 47 zileuton CR 47 investigational protease inhibitor 47 CD# CEA 47 clinical pharmacology studies 47 OSI Tarceva 47 Locteron ® 47 ReN# 47 miRNA biomarkers 47 Solorel 47 quinacrine 47 XmAb# 47 ChronVac C ® 47 PEG IFN 47 Solzira 47 Oncotype 47 double blinded placebo 47 placebo controlled clinical 47 subcutaneous methylnaltrexone 47 BRAF inhibitors 47 Pancreate 47 ARRY # 47 Aerosurf 47 antibody humanization 47 Zalypsis 47 Rhucin R 47 antisense inhibitor 47 Phase III Clinical Trials 47 Radezolid 47 generation URAT1 inhibitor 47 Phase II 47 oral opioid modulator 47 endothelin antagonist 47 Epanova 47 anti angiogenic agent 47 develop GED aPC 47 AVONEX PEN 47 Phase IIIB IV 47 MVA MUC1 IL2 47 P#X# antagonist 47 Ophena 47 Miikana Therapeutics 47 riociguat 47 teplizumab 47 OvaRex MAb 47 recurrent metastatic ovarian cancer 47 OraTest R 47 GeneSightRx 47 accumulate preferentially 47 AMD# [002] 47 Alexza Staccato 47 STEDESA 47 vitro toxicology 47 ranpirnase 47 multitargeted 47 confirmatory Phase 3 47 bispecific antibody 47 PRESEPT study 47 Phase 2a 47 HIV integrase inhibitor 47 RhuDex TM 47 KB# [002] 47 BC SeraPro 47 carbohydrate polymers 47 Hematide ™ peginesatide 47 SU# [003] 47 diagnostic biomarker 47 GRNOPC1 47 Marketing Authorisation Application MAA 47 BLP# 47 Phase 2b 47 Encysive Pharmaceuticals Nasdaq ENCY 47 PI3K inhibitors 47 TransVax tm 47 fusion inhibitor 47 Phase Ia 47 pentostatin 47 Gentamicin Surgical Implant 47 TRO# 47 MyoCell SDF 1 47 Tanespimycin 47 ICA # 47 Phase #/#a clinical 47 Lisofylline LSF 47 delta opioid receptor 47 senicapoc 47 MEND CABG 47 LO LOESTRIN FE 47 vascular disrupting agent 47 multicenter randomized controlled 47 Phase IIA 47 VersaFilm 47 Rescula 47 systemic RNAi 47 eligen 47 naronapride 47 Biologic License Application BLA 47 ProCord 47 Alequel TM 47 Toraymyxin 47 outlicensed 47 NASDAQ GNTA 47 molecularly targeted therapies 46 PORxin TM platforms 46 aclidinium bromide